Heather Bresch's appearance at industry summit came after she declined to attend a congressional hearing scheduled for the same day.
The search-engine giant says that one in 20 online searches are related to healthcare, and more users are using mobile to consume media.
Here's a look at 100 experimental therapies in late-stage clinical trials.
Regeneron and Pfizer CEOs argue about the industry's reputation; Mylan CEO defends the EpiPen; Pfizer and IBM to partner on cancer immunotherapies
Valeant doesn't plan to offload Salix; heart docs back Califf as commish; Saunders says pricing issues aren't affected by election
The bill includes two provisions that would address drugmakers' calls for clarity on sharing off-label information with payers and regulators.
How VR, nanotechnology, and 3D printing could improve the value of healthcare; 100 experimental therapies in late-stage clinical trials; Kite Pharma plans "controlled" launch of CAR-T therapy
Astellas Pharma is searching for Xtandi successor; Novo Nordisk says Tresiba is safer than Lantus; Pfizer awards Nexium account to Grey
Companies such as Eli Lilly and Medtronic have launched branded apps for their products, but experts say they don't make sense for all medicines.
The bill includes provisions to investigate the usefulness of off-label information but will no longer exempt drugmakers from reporting CME payments.
The drugmaker still views Instagram as a viable marketing platform, however.
Trump selects Price as head of HHS; Warren criticizes 21st Century Cures; GSK CEO says companies will have to get used to making less money
The drugmaker's new EVP of worldwide commercial operations also talks about tackling medication access, product launches, and starting a commercial team from scratch.
J&J in talks to buy Actelion; Novo Nordisk pulls ads on Breitbart News; Takeda to market Ninlaro in Europe
A new survey found that U.S. pharma marketers prefer using social media and mobile apps to reach healthcare providers.
Lilly's experimental Alzheimer's drug fails in another trial; two more patients die during trial for Juno's CAR-T therapy; NEJM launches platform in China
The FDA approved Sanofi's Soliqua and Novo Nordisk's Xultophy on Tuesday.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Featured Work: Kennedy Health brings sophisticated healthcare to South Jersey, and we wanted this ...
- The 2017 pipeline report: What to know about next year's launches
- Five things for pharma marketers to know: Monday, November 28, 2016
- Lilly's branded app for Trulicity looks to address adherence
- Five things for pharma marketers to know: Tuesday, November 29, 2016
- Lawmakers cut CME exemption from 21st Century Cures Act
- Boehringer Ingelheim launches gamified support program
- Omnicom merges AgencyRx, Flashpoint and three other agencies to form DDB Health
- No free lunch for docs: Sponsored meals linked to more prescriptions
- Non-profit behind Free Killer Tan wants parents to practice sun safety
- Allergan draws on A-list celebs to drive engagement
- Prescription drug spending rises 9% in 2015, to $324 billion
- As users move to mobile, Google says they made 200 million queries for info about cancer drugs
- Five things for pharma marketers to know: Friday, December 2, 2016
- Mylan CEO defends EpiPen strategy, questions pricing model in the U.S.
- Five things for pharma marketers to know: Thursday, December 1, 2016